Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 43 15 17 71
Actinic Keratosis 71
Hyperkeratosis 71


External Ids:

Disease Ontology 12 DOID:161
MeSH 43 D007642
NCIt 49 C34747
SNOMED-CT 67 254666005
UMLS 71 C0022593 C0022602 C0870082

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis, seborrheic and actinic keratosis, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Tazarotene and Metformin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are cardiovascular system and cellular

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 468)
# Related Disease Score Top Affiliating Genes
1 keratosis, seborrheic 34.9 TP53 PIK3CA KRT10 FGFR3
2 actinic keratosis 34.8 TP53 FLG DSG2
3 keratosis follicularis spinulosa decalvans 34.8 SAT1 MBTPS2 LRP1
4 erythrokeratodermia variabilis et progressiva 1 33.6 KRT1 GJB2 GJA1
5 punctate palmoplantar keratoderma 33.3 SERPINB7 GJB2 AAGAB
6 ichthyosis vulgaris 33.2 KRT10 KRT1 FLG
7 palmoplantar keratoderma, epidermolytic 33.2 KRT9 KRT10 KRT1 GJB2 FLG CTSC
8 palmoplantar keratoderma and congenital alopecia 1 33.2 GJB2 GJA1
9 naxos disease 33.1 GJA1 DSP DSG2
10 striate palmoplantar keratoderma 32.9 SERPINB7 KRT10 KRT1 DSP CTSC
11 palmoplantar keratosis 32.9 SLURP1 SERPINB7 MBTPS2 KRT9 KRT10 KRT1
12 ifap syndrome with or without bresheck syndrome 32.8 MBTPS2 GJB2
13 diffuse palmoplantar keratoderma 32.8 KRT9 KRT1 DSP
14 palmoplantar keratoderma, nonepidermolytic 32.7 KRT1 GJA1 DSP DSG2
15 acrokeratoderma, hereditary papulotranslucent 32.1 KRT9 KRT1 GJB2
16 dermatosis papulosa nigra 32.1 PIK3CA FGFR3
17 lichen planus 31.6 TP53 KRT10 KRT1 FLG
18 keratoacanthoma 31.2 TP53 KRT10 FLG
19 papilloma 31.2 TP53 KRT10 KRT1 FLG FGFR3
20 skin atrophy 31.1 MBTPS2 GJA1 FLG
21 acanthoma 30.9 TP53 PIK3CA KRT10 KRT1 FGFR3
22 porokeratosis 30.8 TP53 KRT1 GJB2 FLG FGFR3
23 hypotrichosis 30.8 MBTPS2 GJB2 GJA1 FLG CTSC
24 discoid lupus erythematosus 30.7 KRT10 FLG
25 ichthyosis 30.7 POMP MBTPS2 KRT10 KRT1 GJB2 GJA1
26 familial woolly hair syndrome 30.7 MBTPS2 GJA1 DSP DSG2
27 epidermolytic hyperkeratosis 30.6 KRT9 KRT10 KRT1 FLG DSP
28 large cell acanthoma 30.6 TP53 KRT10
29 nevus, epidermal 30.5 PIK3CA KRT10 KRT1 GJB2 FGFR3
30 epidermolysis bullosa 30.5 KRT10 KRT1 FLG DSP
31 ectodermal dysplasia 30.4 GJB2 GJA1 FGFR3 DSP
32 pseudoainhum 30.4 GJB2 GJA1
33 skin squamous cell carcinoma 30.3 TP53 KRT10 KRT1
34 cardiomyopathy, dilated, with woolly hair and keratoderma 30.2 GJA1 DSP DSG2
35 bart-pumphrey syndrome 30.2 GJB2 GJA1
36 knuckle pads 30.2 KRT9 GJB2 GJA1
37 pachyonychia congenita 1 29.9 MBTPS2 KRT9 KRT10 KRT1 FLG DSP
38 skin disease 29.7 TP53 SLURP1 KRT9 KRT10 KRT1 GJB2
39 keratoderma, palmoplantar, with deafness 29.5 GJB2 GJA1
40 keratosis pilaris atrophicans 12.6
41 keratosis follicularis spinulosa decalvans, x-linked 12.6
42 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.6
43 keratosis follicularis, dwarfism, and cerebral atrophy 12.5
44 keratosis follicularis spinulosa decalvans, autosomal dominant 12.5
45 keratosis, focal palmoplantar and gingival 12.5
46 inverted follicular keratosis 12.4
47 vulvar inverted follicular keratosis 12.4
48 vulvar seborrheic keratosis 12.3
49 inflamed seborrheic keratosis 12.3
50 keratosis palmoplantaris striata iii 12.3

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):

Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:

Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:

pruritus, exanthema, trichorrhexis invaginata

MGI Mouse Phenotypes related to Keratosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 ATP2A2 DSG2 DSP GJA1 GJB2 KRT1
2 cellular MP:0005384 9.93 ATP2A2 CTSC DSG2 DSP FGFR3 GJA1
3 growth/size/body region MP:0005378 9.73 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
4 integument MP:0010771 9.4 ATP2A2 CTSC DSG2 DSP FGFR3 GJA1

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
Metformin Approved Phase 4 657-24-9 14219 4091
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Prilocaine Approved Phase 4 721-50-6 4906
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
carbamide peroxide Approved Phase 4 124-43-6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
Aminolevulinic acid Approved Phase 4 106-60-5 137
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
22 Sunscreening Agents Phase 4
23 Keratolytic Agents Phase 4
24 Hypoglycemic Agents Phase 4
25 Cyclooxygenase Inhibitors Phase 4
26 Anti-Arrhythmia Agents Phase 4
27 Retinol palmitate Phase 4
28 retinol Phase 4
29 Lidocaine, Prilocaine Drug Combination Phase 4
30 Sodium Channel Blockers Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Anesthetics, Local Phase 4
33 Hormones Phase 4
34 Triamcinolone diacetate Phase 4
35 Hormone Antagonists Phase 4
36 glucocorticoids Phase 4
37 triamcinolone acetonide Phase 4
38 Triamcinolone hexacetonide Phase 4
39 Trace Elements Phase 4
40 Micronutrients Phase 4
41 Vitamins Phase 4
42 Nutrients Phase 4
43 Calciferol Phase 4
44 Calcium, Dietary Phase 4
45 Viscosupplements Phase 4
46 Anti-Infective Agents, Local Phase 4
47 Anti-Infective Agents Phase 4
48 Chlorhexidine gluconate Phase 4
49 Disinfectants Phase 4
50 Analgesics, Non-Narcotic Phase 4

Interventional clinical trials:

(show top 50) (show all 368)
# Name Status NCT ID Phase Drugs
1 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
2 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
3 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
4 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Unknown status NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
7 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
8 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
9 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
10 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
11 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
12 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
13 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
14 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
16 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
17 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
18 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
19 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
20 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
21 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
22 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
23 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
24 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
25 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
26 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
27 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
28 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
29 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
30 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
31 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
32 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
33 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
34 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
35 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
36 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
37 Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
38 The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study Completed NCT03212625 Phase 4 Urea Cream 20%;Placebos
39 Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial Completed NCT00599807 Phase 4
40 Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome. Completed NCT02097615 Phase 4
41 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
42 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
43 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Recruiting NCT03963102 Phase 4 Ameluz
44 Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
45 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
46 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
47 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
48 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
49 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Diclofenac Potassium
Diclofenac Sodium

Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

Skin, Testes, T Cells, Breast, Tongue, Lung, Kidney

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 10052)
# Title Authors PMID Year
Normal-subtracted preprocessing of Raman spectra aiming to discriminate skin actinic keratosis and neoplasias from benign lesions and normal skin tissues. 61
31853808 2020
Identification of putative genetic modifying factors that influence the development of Papillon-Lefévre or Haim-Munk syndrome phenotypes. 61
31925812 2020
Screening and Intervention for Skin Cancer in the Galapagos. 61
32355081 2020
Clinicopathologic Diagnostic Criteria for Vulvar Lichen Planus. 61
32205763 2020
Segmental seborrheic keratosis-like keratinocyte epidermal nevus. 61
32424828 2020
Purpuric subungual hyperkeratosis: a marker for systemic amyloidosis. 61
32141065 2020
Nodular, ulcerated seborrhoeic keratosis. 61
31919882 2020
Actinic keratosis arising in an epidermal cyst. 61
32461383 2020
Nail dermoscopy (onychoscopy) findings in the diagnosis of primary onychomycosis: A cross-sectional study. 61
32415047 2020
Effects of MAL-PDT, ingenol mebutate and diclofenac plus hyaluronate gel monitored by high-frequency ultrasound and digital dermoscopy in actinic keratosis - a randomized trial. 61
31793041 2020
The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study. 61
32301503 2020
Treatment monitoring of 5-Fluorouracil 0.5%/Salicylic Acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. 61
32478958 2020
Comparing the efficacy of field treatments for actinic keratosis: a critical appraisal of a randomized trial in the New England Journal of Medicine. 61
31529471 2020
Efficacy of lidocaine 7 %, tetracaine 7 % self-occlusive cream in reducing MAL-cPDT-associated pain in subjects with actinic keratosis: A randomized, single-blind, vehicle-controlled trial (The "3P-Trial"). 61
32294560 2020
Possible strategy to prevent recurrence of actinic keratosis after treatment field-direct. 61
32542965 2020
The validity of diagnostic and treatment codes for actinic keratosis in electronic health records. 61
31797355 2020
Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study. 61
32506248 2020
Detection of human papillomaviruses in paired healthy skin and actinic keratosis by next generation sequencing. 61
32222599 2020
Field cancerization treatment using topical photodynamic therapy: A comparison between two aminolevulinate derivatives. 61
31821900 2020
[Actinic keratoses : Current guideline and practical recommendations]. 61
32472149 2020
Identifying Type III Sulcus: Patient Characteristics and Endoscopic Findings. 61
32571136 2020
An Investigation of the Stability of Patients' Treatment Preferences Over the Course of a Clinical Trial. 61
32540236 2020
Chronic expression of p16INK4a in the epidermis induces Wnt-mediated hyperplasia and promotes tumor initiation. 61
32483135 2020
Ectodermal dysplasia-skin fragility syndrome: Two new cases and review of this desmosomal genodermatosis. 61
32248567 2020
Fatal hyperkeratosis syndrome in four siblings due to dolichol kinase deficiency. 61
32250540 2020
Erosive pustular dermatosis of the scalp: a multicentre study. 61
31954062 2020
Mutations in KRT10 in epidermolytic acanthoma. 61
32045015 2020
Keratin 5-Cre-driven deletion of Ncstn in an acne inversa-like mouse model leads to a markedly increased IL-36a and Sprr2 expression. 61
31884525 2020
Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us? 61
32530503 2020
Biomononitoring of environmental exposure to inorganic arsenic. 61
32540815 2020
Cutaneous horn associated to seborrheic keratosis in eyelid margin. 61
32565018 2020
The Mast Cell-SCF-CB1 Interaction Is a Key Player in Seborrheic Keratosis. 61
32578480 2020
The Prognostic Value of Podoplanin Expression in Nonmelanoma Skin Cancers: Correlation With Lymphatic Vessel Density. 61
31688008 2020
33% hydrogen peroxide as a Neoadjuvant treatment in the surgical excision of non-melanoma skin cancers: a case series. 61
32487195 2020
Acquired Epidermodysplasia Verruciformis in the Setting of Renal Transplant. 61
32568838 2020
Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis. 61
32563057 2020
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. 61
32234429 2020
Dose and time effects of solar-simulated ultraviolet radiation on the in vivo human skin transcriptome. 61
31529490 2020
Reflectance confocal microscopy. Part II. Diagnostic criteria of common benign and malignant neoplasms, dermoscopic and histopathological correlates of key confocal criteria, and diagnostic algorithms. 61
32565210 2020
Successful Treatment of Keratosis Follicularis Spinulosa Decalvans With an 800-nm Diode Laser. 61
30893172 2020
Clinical variability of the GJB4:c.35G > A gene variant: a study of a large Brazilian erythrokeratodermia pedigree. 61
32311086 2020
Noonan syndrome with multiple Giant cell lesions, management and treatment with surgery and interferon alpha-2a therapy: Case report. 61
32065515 2020
Successful treatment of recalcitrant nodular prurigo with tofacitinib. 61
32484964 2020
High-frequency (20 MHz) high-intensity focused ultrasound: New Treatment of actinic keratosis, basal cell carcinoma, and Kaposi sarcoma. An open-label exploratory study. 61
32557832 2020
Pre-mRNA processing factor 3 enhances the progression of keratinocyte-derived cutaneous squamous cell carcinoma by regulating the JAK2/STAT3 pathway. 61
32483193 2020
Verrucous hyperkeratosis with predominant involvement of the left side of the body and concomitant onychodystrophy in a 17-year-old girl. 61
32515052 2020
Current therapies for actinic keratosis. 61
32012240 2020
Principal component analysis of seven skin-ageing features identifies three main types of skin ageing. 61
31519034 2020
High-risk body sites for actinic keratosis in outdoor and indoor workers: A retrospective review. 61
32561289 2020
Late development of pustular, erosive lesions in the muzzle of calves inoculated with Pseudocowpox virus. 61
32169495 2020

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.17 TP53 SERPINB7 SAT1 POMP PIK3CA MBTPS2
2 intermediate filament GO:0005882 9.35 KRT9 KRT10 KRT1 FLG DSP
3 intercalated disc GO:0014704 9.33 GJA1 DSP DSG2
4 fascia adherens GO:0005916 9.26 GJA1 DSP
5 cornified envelope GO:0001533 9.02 KRT10 KRT1 FLG DSP DSG2

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.72 KRT9 DSP ATP2A2
2 response to ischemia GO:0002931 9.63 TP53 GJB2 GJA1
3 keratinocyte differentiation GO:0030216 9.61 KRT10 FLG DSP
4 keratinization GO:0031424 9.55 KRT9 KRT10 KRT1 DSP DSG2
5 protein heterotetramerization GO:0051290 9.54 KRT10 KRT1
6 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.52 TP53 MBTPS2
7 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.51 DSP DSG2
8 gap junction assembly GO:0016264 9.49 GJB2 GJA1
9 cell communication by electrical coupling GO:0010644 9.48 GJB2 GJA1
10 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.4 DSP DSG2
11 desmosome organization GO:0002934 9.37 DSP DSG2
12 epididymis development GO:1905867 9.32 GJB2 GJA1
13 bone maturation GO:0070977 9.26 MBTPS2 FGFR3
14 peptide cross-linking GO:0018149 9.26 KRT10 KRT1 FLG DSP
15 cornification GO:0070268 9.1 KRT9 KRT10 KRT1 FLG DSP DSG2

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.56 KRT9 KRT10 FLG DSP
2 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.16 DSP DSG2
3 gap junction channel activity involved in cell communication by electrical coupling GO:1903763 8.96 GJB2 GJA1
4 structural constituent of epidermis GO:0030280 8.8 KRT10 KRT1 FLG

Sources for Keratosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....